Translational Research: Assay Development
The identification and testing of agents acting through a particular target that may modify a disease’s course typically require a set of reliable and reproducible assays to demonstrate the efficacy, selectivity, and potency of the potential therapeutic candidate. Such assays may be used to identify hits from high throughput screening campaigns, refine peptides by molecular panning, or assess in vivo properties of agents.
-
Disease
Biology -
Unvalidated
TargetTarget IDPutative
Targets -
Nominated
TargetAssay DevelopmentScreenable
Assays -
Target AssayScreeningHits and
Starting Points -
HitHit to LeadLead Series
-
Lead
CompoundLead
OptimizationPotential
Therapeutic
Leads -
Pre‑clinical
CandidatePre‑clinical
DevelopmentClinical
Therapeutic
Candidate -
Clinical
CandidateClinical
DevelopmentClinical Proof
of Concept -
Licensing and
Commercializa-
tion PartnersMarket-ready
Therapeutics
NIH Funding Opportunities
PA-16-374, Assay Development and Screening to Discover Therapeutic or Imaging Agents for Diseases of Interest to the NIDDK (R01) has expired. The NIDDK is still interested in supporting this type of translational science and another potential option is to apply to the Parent R01 NOFO (PA-20-185) and consider requesting review assignment to any of CSR’s Drug Synthesis, Discovery, Disposition, and Xenobiotics study sections, or another relevant review panel. Applicants should consult the NIH/CSR study section descriptions before requesting a specific review panel.
Please reach out to one of the Staff Contacts listed below if you have any questions.
Related Resources
- Academic Drug Discovery Consortium
- NIH Molecular Libraries and Imaging
- PubChem
- NIDDK Small Business Programs
Staff Contacts
Division of Kidney, Urologic, and Hematologic Diseases
Dr. Anna Sadusky
Division of Digestive Diseases and Nutrition
Dr. Bonnie Burgess-Beusse
Division of Diabetes, Endocrinology, and Metabolic Diseases
Dr. Yan Li